From Wikipedia: A biosimilar (also known as follow-on biologic or subsequent entry biologic) is a biologic medical product which is almost an identical copy of an original product that is manufactured by a different company. Biosimilars are officially approved versions of original "innovator" products, and can be manufactured when the original product's patent expires.
Note: at this time, due to prioritization, we will not be adding literature directly related to the evaluation of biosimilars (e.g., an RCT that compares the original product to a biosimilar). If this is content that you desire to see on HemOnc.org, please let us know through the contact email.
Pages in category "Biosimilars"
The following 9 pages are in this category, out of 9 total.